Janux Therapeutics (JANX) EBITDA Margin (2021 - 2026)
Janux Therapeutics' EBITDA Margin came in at -304.15% for Q2 2026, up 599.79 percentage points from the prior quarter.
Powered by 
Analysis
Janux Therapeutics (JANX) EBITDA Margin (2021 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Janux Therapeutics reported EBITDA Margin of -590.23%, up 31937.57 percentage points year-over-year; for FY2025, it came in at -1556.38%, down 642.26 percentage points from FY2024.
- EBITDA Margin has declined in each of the last three years, with a four-year change of -654.10 percentage points (FY2021 to FY2025).
- Going back by year, EBITDA Margin was -914.12% in FY2024 (-35.44 pp), -878.68% in FY2023 (-109.41 pp), -769.28% in FY2022 (+133.01 pp) and -902.28% in FY2021.
- The Q2 2026 figure represents the highest quarterly EBITDA Margin since Q2 2024.
- The fastest year-over-year change in EBITDA Margin over five years came in Q3 2025 (a gain of 7700.79 percentage points), and the weakest in Q3 2024 (a drop of 7439.91 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Janux Therapeutics | 1.01 Bn | 1.01 Bn | - | -304.15% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -304.15% |
| Mar 31, 2026 | -903.94% |
| Sep 30, 2025 | -347.50% |
| Sep 30, 2024 | -8,048.29% |
| Jun 30, 2024 | -149.67% |
| Mar 31, 2024 | -1,567.81% |
| Dec 31, 2023 | -634.13% |
| Sep 30, 2023 | -608.38% |
| Jun 30, 2023 | -1,918.35% |
| Mar 31, 2023 | -968.16% |
| Dec 31, 2022 | -627.87% |
| Sep 30, 2022 | -980.31% |
| Jun 30, 2022 | -725.29% |
| Mar 31, 2022 | -847.14% |
| Dec 31, 2021 | -830.82% |
| Sep 30, 2021 | -938.40% |
| Jun 30, 2021 | -1,294.40% |
| Mar 31, 2021 | -598.68% |
API Access
Janux Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=JANX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "JANX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=JANX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();